Report cover image

Europe Hemophilia Market Size, Share & Industry Trends Analysis Report By Distribution Channel, By Type (Hemophilia A, Hemophilia B), By Treatment Type (Prophylaxis, On-demand, and Cure), By Therapy, By Country and Growth Forecast, 2023 - 2030

Publisher Knowledge Based Value (KBV) Research
Published Jul 31, 2023
Length 139 Pages
SKU # KBV18138464

Description

Europe Hemophilia Market Size, Share & Industry Trends Analysis Report By Distribution Channel, By Type (Hemophilia A, Hemophilia B), By Treatment Type (Prophylaxis, On-demand, and Cure), By Therapy, By Country and Growth Forecast, 2023 - 2030


The Europe Hemophilia Market would witness market growth of 5.7% CAGR during the forecast period (2023-2030).

The market is expanding as a result of a number of causes, including the rising prevalence of hemophilia, supportive government initiatives, and increased research and development for the creation of novel medicines. The growing target demographic, higher diagnostic rates, more people being diagnosed with the condition, and an increase in preventative therapy for hemophilia are all factors that support market expansion.

Due to the requirement for more clotting factors or a different type of clotting factor, treating bleeding episodes becomes incredibly challenging, and the expense of care for a person with an inhibitor can soar. Inhibitors frequently cause increased joint disease and other bleeding-related issues that lower the quality of life.

The European Commission has granted BioMarin's ROCTAVIANTM (valoctocogene roxaparvovec) gene therapy conditional marketing authorization for the management of severe hemophilia A. The therapy is specifically developed for adult patients that don't have a history of Factor VIII inhibitors and with no detectable antibodies to adeno-associated virus serotype 5 (AAV5). Additionally, the EC agreed with the European Medicines Agency's (EMA) proposal that Roctavian keep its orphan medicine status, allowing it a 10-year window of market exclusivity. Therefore, similar efforts and developments in the coming years will propel the market's growth.

The Germany market dominated the Europe Hemophilia Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $1,114.3 million by 2030. The UK market is exhibiting a CAGR of 4.8% during (2023 - 2030). Additionally, The France market would experience a CAGR of 6.5% during (2023 - 2030).

Based on Distribution Channel, the market is segmented into Specialty Pharmacies, and Hospital Pharmacies. Based on Type, the market is segmented into Hemophilia A, Hemophilia B, and Others. Based on Treatment Type, the market is segmented into Prophylaxis, On-demand, and Cure. Based on Therapy, the market is segmented into Factor Replacement Therapy (Recombinant Factor Concentrates, and Plasma-derived Factor Concentrates), Desmopressin & Fibrin Sealants, and Gene Therapy & Monoclonal Antibodies. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Takeda Pharmaceutical Company Limited, CSL Limited (CSL Behring), Pfizer, Inc., Bayer AG, F. Hoffmann-La Roche Ltd., Novo Nordisk A/S, Octapharma AG, BioMarin Pharmaceutical Inc., Swedish Orphan Biovitrum AB (Investor AB) and Sanofi S.A.

Scope of the Study

Market Segments covered in the Report:

By Distribution Channel
  • Specialty Pharmacies
  • Hospital Pharmacies
By Type
  • Hemophilia A
  • Hemophilia B
  • Others
By Treatment Type
  • Prophylaxis
  • On-demand
  • Cure
By Therapy
  • Factor Replacement Therapy
  • Recombinant Factor Concentrates
  • Plasma-derived Factor Concentrates
  • Desmopressin & Fibrin Sealants
  • Gene Therapy & Monoclonal Antibodies
By Country
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
Companies Profiled
  • Takeda Pharmaceutical Company Limited
  • CSL Limited (CSL Behring)
  • Pfizer, Inc.
  • Bayer AG
  • F. Hoffmann-La Roche Ltd.
  • Novo Nordisk A/S
  • Octapharma AG
  • BioMarin Pharmaceutical Inc.
  • Swedish Orphan Biovitrum AB (Investor AB)
  • Sanofi S.A.
Unique Offerings from KBV Research
  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

139 Pages
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Hemophilia Market, by Distribution Channel
1.4.2 Europe Hemophilia Market, by Type
1.4.3 Europe Hemophilia Market, by Treatment Type
1.4.4 Europe Hemophilia Market, by Therapy
1.4.5 Europe Hemophilia Market, by Country
1.5 Methodology for the research
Chapter 2. Market At a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
Chapter 4. Competition Analysis - Global
4.1 KBV Cardinal Matrix
4.2 Recent Industry Wide Strategic Developments
4.2.1 Partnerships, Collaborations and Agreements
4.2.2 Product Launches and Product Expansions
4.2.3 Acquisition and Mergers
4.2.4 Trials and Approvals
4.3 Top Winning Strategies
4.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
4.3.2 Key Strategic Move: (Product Launches and Product Expansions : 2017, Jun – 2021, Jun) Leading Players
4.4 Porter Five Forces Analysis
Chapter 5. Europe Hemophilia Market by Distribution Channel
5.1 Europe Specialty Pharmacies Market by Country
5.2 Europe Hospital Pharmacies Market by Country
Chapter 6. Europe Hemophilia Market by Type
6.1 Europe Hemophilia A Market by Country
6.2 Europe Hemophilia B Market by Country
6.3 Europe Others Market by Country
Chapter 7. Europe Hemophilia Market by Treatment Type
7.1 Europe Prophylaxis Market by Country
7.2 Europe On-demand Market by Country
7.3 Europe Cure Market by Country
Chapter 8. Europe Hemophilia Market by Therapy
8.1 Europe Factor Replacement Therapy Market by Country
8.2 Europe Hemophilia Market by Factor Replacement Therapy Type
8.2.1 Europe Recombinant Factor Concentrates Market by Country
8.2.2 Europe Plasma-derived Factor Concentrates Market by Country
8.3 Europe Desmopressin & Fibrin Sealants Market by Country
8.4 Europe Gene Therapy & Monoclonal Antibodies Market by Country
Chapter 9. Europe Hemophilia Market by Country
9.1 Germany Hemophilia Market
9.1.1 Germany Hemophilia Market by Distribution Channel
9.1.2 Germany Hemophilia Market by Type
9.1.3 Germany Hemophilia Market by Treatment Type
9.1.4 Germany Hemophilia Market by Therapy
9.1.4.1 Germany Hemophilia Market by Factor Replacement Therapy Type
9.2 UK Hemophilia Market
9.2.1 UK Hemophilia Market by Distribution Channel
9.2.2 UK Hemophilia Market by Type
9.2.3 UK Hemophilia Market by Treatment Type
9.2.4 UK Hemophilia Market by Therapy
9.2.4.1 UK Hemophilia Market by Factor Replacement Therapy Type
9.3 France Hemophilia Market
9.3.1 France Hemophilia Market by Distribution Channel
9.3.2 France Hemophilia Market by Type
9.3.3 France Hemophilia Market by Treatment Type
9.3.4 France Hemophilia Market by Therapy
9.3.4.1 France Hemophilia Market by Factor Replacement Therapy Type
9.4 Russia Hemophilia Market
9.4.1 Russia Hemophilia Market by Distribution Channel
9.4.2 Russia Hemophilia Market by Type
9.4.3 Russia Hemophilia Market by Treatment Type
9.4.4 Russia Hemophilia Market by Therapy
9.4.4.1 Russia Hemophilia Market by Factor Replacement Therapy Type
9.5 Spain Hemophilia Market
9.5.1 Spain Hemophilia Market by Distribution Channel
9.5.2 Spain Hemophilia Market by Type
9.5.3 Spain Hemophilia Market by Treatment Type
9.5.4 Spain Hemophilia Market by Therapy
9.5.4.1 Spain Hemophilia Market by Factor Replacement Therapy Type
9.6 Italy Hemophilia Market
9.6.1 Italy Hemophilia Market by Distribution Channel
9.6.2 Italy Hemophilia Market by Type
9.6.3 Italy Hemophilia Market by Treatment Type
9.6.4 Italy Hemophilia Market by Therapy
9.6.4.1 Italy Hemophilia Market by Factor Replacement Therapy Type
9.7 Rest of Europe Hemophilia Market
9.7.1 Rest of Europe Hemophilia Market by Distribution Channel
9.7.2 Rest of Europe Hemophilia Market by Type
9.7.3 Rest of Europe Hemophilia Market by Treatment Type
9.7.4 Rest of Europe Hemophilia Market by Therapy
9.7.4.1 Rest of Europe Hemophilia Market by Factor Replacement Therapy Type
Chapter 10. Company Profiles
10.1 Swedish Orphan Biovitrum AB (Investor AB)
10.1.1 Company Overview
10.1.2 Financial Analysis
10.1.3 Segmental and Regional Analysis
10.1.4 Research & Development Expenses
10.1.5 SWOT Analysis
10.2 Takeda Pharmaceutical Company Limited
10.2.1 Company Overview
10.2.2 Financial Analysis
10.2.3 Regional Analysis
10.2.4 Research & Development Expense
10.2.5 Recent strategies and developments:
10.2.5.1 Trials and Approvals:
10.2.5.2 Product Launches and Product Expansions:
10.3 Pfizer, Inc.
10.3.1 Company Overview
10.3.2 Financial Analysis
10.3.3 Regional & Segmental Analysis
10.3.4 Research & Development Expense
10.3.4.1 Partnerships, Collaborations, and Agreements:
10.3.4.2 Acquisition and Mergers:
10.4 CSL Limited (CSL Behring)
10.4.1 Company Overview
10.4.2 Financial Analysis
10.4.3 Segmental and Regional Analysis
10.4.4 Research & Development Expense
10.4.5 Recent strategies and developments:
10.4.5.1 Trials and Approvals:
10.4.5.2 Acquisition and Mergers:
10.4.6 SWOT Analysis
10.5 Octapharma AG
10.5.1 Company Overview
10.5.2 Financial Analysis
10.5.3 Research & Development Expenses
10.5.4 Recent strategies and developments:
10.5.4.1 Trials and Approvals:
10.5.5 SWOT Analysis
10.6 Bayer AG
10.6.1 Company Overview
10.6.2 Financial Analysis
10.6.3 Segmental and Regional Analysis
10.6.4 Research & Development Expense
10.6.5 Recent strategies and developments:
10.6.5.1 Partnerships, Collaborations, and Agreements:
10.6.5.2 Acquisition and Mergers:
10.6.6 SWOT Analysis
10.7 F. Hoffmann-La Roche Ltd.
10.7.1 Company Overview
10.7.2 Financial Analysis
10.7.3 Segmental and Regional Analysis
10.7.4 Research & Development Expense
10.7.5 SWOT Analysis
10.8 Novo Nordisk A/S
10.8.1 Company Overview
10.8.2 Financial Analysis
10.8.3 Segmental & Regional Analysis
10.8.4 Research & Development Expenses
10.8.5 Recent strategies and developments:
10.8.5.1 Partnerships, Collaborations, and Agreements:
10.8.5.2 Product Launches and Product Expansions:
10.8.5.3 Acquisition and Mergers:
10.8.6 SWOT Analysis
10.9 BioMarin Pharmaceutical Inc.
10.9.1 Company Overview
10.9.2 Financial Analysis
10.9.3 Regional Analysis
10.9.4 Research & Development Expenses
10.9.5 Recent strategies and developments:
10.9.5.1 Trials and Approvals:
10.9.6 SWOT Analysis
10.10. Sanofi S.A.
10.10.1 Company Overview
10.10.2 Financial Analysis
10.10.3 Segmental and Regional Analysis
10.10.4 Research & Development Expense
10.10.5 Recent strategies and developments:
10.10.5.1 Trials and Approvals:

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us